Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.

@article{Puyang2010MechanismOR,
  title={Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.},
  author={Xiaoling Puyang and Danielle L Poulin and Joanna E Mathy and Leah J Anderson and Sue Ma and Zheng Felix Fang and Shejin Zhu and Kai Lin and Roger Fujimoto and Teresa Compton and Brigitte Wiedmann},
  journal={Antimicrobial agents and chemotherapy},
  year={2010},
  volume={54 5},
  pages={1981-7}
}
The current standard of care for hepatitis C virus (HCV) infection, pegylated alpha interferon in combination with ribavirin, has a limited response rate and adverse side effects. Drugs targeting viral proteins are in clinical development, but they suffer from the development of high viral resistance. The inhibition of cellular proteins that are essential… CONTINUE READING